MDWD News and Press, MediWound Ltd. From 12/20/21

MediWound (NASDAQ:MDWD) announces positive initial data from seven of the maximum fifteen patients in its ongoing Phase 2 pharmacology study of EscharEx, the company’s next-generation enzymatic debridement agent under development for chronic and hard-to-heal wounds. Shares up 2.5%...

Data Demonstrate EscharEx Reduces Biofilm and Bacterial Burden EscharEx is Shown to be Safe with No Observed Safety Issues YAVNE, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company...

YAVNE, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced it has completed patient enrollm...

YAVNE, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Company has received po...

MediWound Ltd. (MDWD) Q3 2021 Results Conference Call November 16, 2021 08:30 AM ET Company Participants Monique Kosse - LifeSci Advisors Sharon Malka - CEO Boaz Gur-Lavie - CFO Conference Call Participants Bryan Bergin - Cowen and Company Ryan Zimmerman - BTIG Kevin DeGeeter - Oppenheimer Sw...

MediWound (NASDAQ:MDWD): Q3 GAAP EPS of -$0.12 beats by $0.01. Revenue of $6.37M (-3.9% Y/Y) beats by $0.7M. Press Release For further details see: MediWound EPS beats by $0.01, beats on revenue

Third Quarter Revenues of $6.4 Million ; Year-to-Date 2021 Revenues Increased 21% C larity on R egulatory P athway for R esubmission of NexoBrid BLA , A nticipated in M id- 2022 Escha...

MediWound (NASDAQ:MDWD) is scheduled to announce Q3 earnings results on Tuesday, November 16th, before market open. The consensus EPS Estimate is -$0.13 (-85.7% Y/Y) and the consensus Revenue Estimate is $5.67M (-14.5% Y/Y). Over the last 3 months, EPS estimates have seen 2 upward revisions a...

AQUA, ARMK, OTCPK:AWLCF, CAN, CWCO, DAO, DAVA, DOYU, ECC, ESEA, FLNG, FUV, GDS, HD, HIVE, OTCQX:IMBBY, JMIA, LILM, MDWD, NTES, OCSL, OZON, REE, SE, TDG, OTCQX:TRSSF, VOD, OTCQX:VYGVF, WMT, ZEPP For Seeking Alpha's full earnings season calendar, click here. For further details see: ...

YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the t...